- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07449702
Uno studio di estensione in aperto di ORKA-001 in partecipanti con psoriasi a placche
Uno studio di estensione in aperto per valutare la sicurezza, la tollerabilità e l'efficacia a lungo termine di ORKA-001 in partecipanti con psoriasi a placche da moderata a grave
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Panoramica dello studio
Descrizione dettagliata
This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Oruka Clinical Trials Information
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
Luoghi di studio
-
-
Alberta
-
Edmonton, Alberta, Canada, T5J 3S9
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Edmonton, Alberta, Canada, T6G 1C3
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Surrey, British Columbia, Canada, V3V 0C6
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Therapeutics Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B IG9
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Ontario
-
Ajax, Ontario, Canada, L1S7K8
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Therapeutics Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
London, Ontario, Canada, N6H 5L5
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Markham, Ontario, Canada, L3P 1X3
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Peterborough, Ontario, Canada, K9J 5K2
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Toronto, Ontario, Canada, M4W 2N4
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Waterloo, Ontario, Canada, N2J 1C4
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Quebec
-
Montreal, Quebec, Canada, H2X2V1
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Therapeutics Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Québec, Quebec, Canada, G1V4X7
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Therapeutics Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85032
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Therapeutics Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Arkansas
-
North Little Rock, Arkansas, Stati Uniti, 72117
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
California
-
Fountain Valley, California, Stati Uniti, 92708
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Los Angeles, California, Stati Uniti, 90045
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Los Angeles, California, Stati Uniti, 90095
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
San Diego, California, Stati Uniti, 92123
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Santa Ana, California, Stati Uniti, 92701
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Santa Monica, California, Stati Uniti, 90403
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Connecticut
-
Cromwell, Connecticut, Stati Uniti, 06416
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Florida
-
Miami, Florida, Stati Uniti, 33126
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Illinois
-
Rolling Meadows, Illinois, Stati Uniti, 60008
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Indiana
-
Plainfield, Indiana, Stati Uniti, 46168
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Kentucky
-
Bowling Green, Kentucky, Stati Uniti, 42104
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Email: clinicaltrials@orukatx.com
-
-
Maryland
-
Rockville, Maryland, Stati Uniti, 20850
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02111
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
New York
-
New York, New York, Stati Uniti, 10023
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
New York, New York, Stati Uniti, 10029
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Mason, Ohio, Stati Uniti, 45040
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Therapeutics Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97201
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Portland, Oregon, Stati Uniti, 97210
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Texas
-
Frisco, Texas, Stati Uniti, 75033
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Therapeutics Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Houston, Texas, Stati Uniti, 77004
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
Webster, Texas, Stati Uniti, 77598
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Therapeutics Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Virginia
-
Norfolk, Virginia, Stati Uniti, 23502
- Reclutamento
- Oruka Therapeutics Investigative Site
-
Contatto:
- Oruka Investigative Site
- Numero di telefono: 781-560-0299
- Email: clinicaltrials@orukatx.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Signed informed consent by participants from previous trial choosing to transition into the OLE.
- Participants who have successfully completed the preceding trial.
- For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
- For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception
Exclusion Criteria:
- Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
- Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
- Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
- Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
- Participant is pregnant or breastfeeding.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: ORKA-001 Once Yearly (High Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Sperimentale: ORKA-001 Once Yearly (Low Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Sperimentale: ORKA-001 Twice Yearly
Participants will receive ORKA-001 every 6 months per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Nessun intervento: No Drug
Participants will receive no drug until protocol defined PASI response criterion is met. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
Lasso di tempo: Day 1 through Week 144
|
Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms. |
Day 1 through Week 144
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Lasso di tempo: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Lasso di tempo: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Lasso di tempo: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Lasso di tempo: Time Frame: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Time Frame: Day 1 through Week 96
|
|
Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline
Lasso di tempo: Day 1 through Week 96
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE
Lasso di tempo: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE
Lasso di tempo: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
PASI Score Over Time
Lasso di tempo: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
IGA Score Over Time
Lasso di tempo: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- ORKA-001-113
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .